2020-2026年醫藥及生物技術領域早期藥物研發（EDR）合作條款及協議

本報告基於數據，全面分析了企業簽訂EDR合作協議的背景和原因，以及支撐這些協議的財務和策略條件。作為業界必備的參考資料，本報告深入剖析了醫藥和生物技術領域EDR合作的結構、談判動態和財務考量。

EDR授權協議通常授予被授權人進一步開發授權人產品或技術的權利或選擇權。這些協議通常包含多個組成部分，可能從聯合研發開始，逐步發展到商業化協議。

本報告詳細分析了醫療保健領域最新的EDR協議，幫助企業了解市場趨勢、評估競爭對手的協議結構並優化自身的談判策略。

生技與製藥業交易撮合者必備的資源

本報告是參與生物製藥交易的業務拓展、法律和財務專業人士不可或缺的資訊來源。

憑藉全面的洞察、龐大的合約資料庫以及對合約文件的直接訪問，本報告是以下用途的終極工具：

• 交易結構與財務條款基準分析
• 優化談判策略
• 評估潛在合作夥伴的彈性和交易行為
• 識別早期藥物研發合作的趨勢和最佳實踐
• 對於那些正在努力建立早期藥物研發合作關係的人士而言，本報告提供了必要的清晰度、數據和策略指導，以確保與合適的合作夥伴達成高價值協議。
• 為何本報告對交易撮合者至關重要
• 深入了解潛在合作夥伴的彈性和談判策略，對於成功建構早期藥物研發交易至關重要。 雖然主要財務條款（例如，預付款、里程碑付款、特許權使用費）提供了一個概覽，但合約文件能夠更深入地揭示這些付款的實際觸發條件和條件。這些關鍵細節往往在新聞稿和傳統資料庫中被忽略。
• 本報告全面涵蓋了自 2020 年以來發布的所有早期藥物研發合作協議，並包含了可用的財務條款。此外，報告還提供了 2,562 個鏈接，指向詳細的線上合約記錄，包括已向美國證券交易委員會 (SEC) 提交的公開合約文件。
• 分析這些協議能夠幫助企業建立符合產業基準的交易結構，並透過最大化潛在收益來獲得競爭優勢。
• 藥物研發早期階段合作趨勢的綜合分析

目錄

摘要整理

第一章：引言

第二章：企業為何在藥物研發早期階段開展合作

• 合作在藥物研發早期階段的作用
  • 藥物研發早期階段的引進許可
  • 藥物研發早期階段的對外許可
• 藥物研發早期階段、臨床前階段及臨床階段交易的差異
• 在藥物研發早期階段達成合作協議的原因
  • 授權人參與早期階段合作的原因交易
  • 被授權人參與早期交易的原因
• 藥物研發早期階段合作協議的未來

第三章 早期藥物研發交易策略與架構

• 公司在哪個階段開展合作？
  • 製藥/生技領域的早期合作
  • 製藥/生技領域的後期合作
• 早期與後期合作－風險與成本比較
• 公司在早期、臨床前和臨床階段的合作上分別投入多少資金？
• 純許可和多組分合作協議
• 純許可協議結構
  • 純許可協議範例
  • 個案研究
• 多組分藥物研發早期合作協議
  • 多組分早期條款範例
  • 個案研究

第四章 早期藥物研發合作：支付策略

• 早期藥物研發支付策略
• 付款方式
  • 標題
  • 預付款
  • 貸款
  • 轉換貸款
  • 公平性
  • 研發資金
  • 許可費
  • 里程碑付款
  • 特許權使用費付款方式
  • Quids（權益）
  • 選擇權付款

第五章：早期藥物研發交易趨勢

• 早期藥物研發合作：依交易類型劃分
• 早期藥物研發合作：依疾病劃分
• 早期藥物研發合作：依技術類型劃分
• 早期藥物研發合作：2020 年至 2026 年最活躍的公司

第六章：早期藥物研發合作中的付款條款

• 早期藥物研發付款條款指南
  • 預付款
  • 里程碑付款
  • 特許權使用費
• 早期藥物研發合作中的付款條款探討：交易資料分析
  • 公開數據
  • 調查數據
• 付款條款分析
  • 要點
  • 預付款
  • 里程碑付款
  • 特許權使用費率

第七章：早期藥物研發合作協議概況

• 早期藥物研發合作協議概況：依金額排序

第八章：早期藥物研發合作最活躍的25家公司

• 早期藥物研發合作最活躍的25家公司

第九章：早期藥物研發合作計畫目錄

• 早期藥物研發合作2020 年至 2026 年的合作關係

第十章：早期藥物研發合作：依研發階段劃分

• 早期藥物研發合作

附錄

• 附錄 1 - 學術機構與非營利組織合作：依公司（A-Z）劃分
• 附錄 2 - 學術機構與非營利組織合作：依產業劃分
• 附錄 3 - 學術機構與非營利組織合作：依研發階段劃分
• 附錄 4 - 學術機構與非營利組織合作：依治療領域劃分
• 附錄 5 - 學術機構與非營利組織合作：依技術劃分
• 生物製藥研究股份有限公司
• 當前合作關係
• 當前協議
• 近期關於當前合作關係的報告標題合作

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2026)

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2026) report offers a comprehensive, data-driven analysis of how and why companies engage in discovery-stage partnering deals and the financial and strategic terms underpinning these agreements. This essential industry resource provides deep insights into the structure, negotiation dynamics, and financial considerations that define early-stage partnerships in the pharmaceutical and biotech sectors.

At the discovery stage, licensing agreements typically grant the licensee rights or options to further develop a licensor's product or technology. These agreements are often multi-component, beginning with collaborative research and development (R&D) and potentially leading to commercialization agreements.

This report provides a detailed breakdown of the latest discovery-stage agreements in the healthcare sector, helping companies identify market trends, evaluate competitive deal structures, and optimize their own negotiation strategies.

A Must-Have Resource for Biotech and Pharma Dealmakers

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report is an indispensable resource for business development, legal, and financial professionals involved in biopharma dealmaking.

With comprehensive insights, a vast deal database, and direct access to contract documents, this report serves as the ultimate tool for:

• Benchmarking deal structures and financial terms
• Optimizing negotiation strategies
• Assessing potential partners' flexibility and deal-making behavior
• Identifying trends and best practices in discovery-stage partnerships
• For those looking to navigate the complex landscape of discovery-stage partnering, this report offers the clarity, data, and strategic guidance needed to secure high-value agreements with the right partners.
• Why This Report is Essential for Dealmakers
• Gaining insight into the flexibility and negotiation strategies of potential partners is crucial in structuring a successful discovery-stage deal. While headline financial terms (e.g., upfront payments, milestones, and royalties) provide a broad overview, contract documents offer a deeper understanding of the actual triggers and conditions for these payments-critical details that press releases and traditional databases often omit.
• This report contains a comprehensive listing of all discovery-stage partnering deals announced since 2020, including financial terms where available. It also features 2,562 links to detailed online deal records, including publicly available contract documents filed with the SEC.
• By analyzing these agreements, companies gain a competitive edge in structuring deals that align with industry benchmarks while maximizing potential returns.
• Comprehensive Analysis of Discovery-Stage Partnering Trends

The first chapters of the report provide a detailed orientation to discovery-stage deal-making and strategic considerations:

Chapter 1 - Introduction to the report

Chapter 2 - Why companies engage in discovery-stage partnerships

Chapter 3 - Strategic approaches and deal structures, with case studies

Chapter 4 - Payment strategies, including upfronts, milestones, and royalties

Chapter 5 - Discovery-stage deal-making analysis categorized by year, therapeutic area, technology type, and key dealmakers

Chapter 6 - Detailed analysis of financial terms, including headline values, upfront payments, milestone triggers, and royalty rates

Chapter 7 - A review of the leading discovery-stage deals by headline value

Chapter 8 - The top 25 most active discovery-stage dealmakers

Chapter 9 - A database of discovery-stage partnering agreements, including contract documents where available

Chapter 10 - A comprehensive directory of all discovery-stage deals announced since 2020

• Each deal record is linked to Current Agreements, a proprietary database that provides easy access to full deal structures, financial terms, and contract documents.
• Key Benefits of the Report
• Comprehensive insights into discovery-stage deal trends since 2020
• Access to key financial terms, including headline values, upfronts, milestones, and royalty structures
• Breakdown of deal structures, with real-world case studies
• Analysis of contractual terms, including real-world clause examples
• Benchmarking of deal terms based on actual agreements
• Due diligence insights to assess the suitability of proposed deal terms for potential partners
• Scope of the Report

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides:

• Analysis of discovery-stage dealmaking trends in the biopharma industry since 2020
• Insight into financial structures, including upfront, milestone, and royalty payments
• Case studies of real-life discovery-stage agreements
• Access to over 2,690 discovery-stage deals, with contract records where available
• Profiles of the most active discovery-stage dealmakers
• Detailed analysis of the highest-value discovery-stage deals

Each deal record is indexed by:

• Company (A-Z)
• Headline value
• Stage of development at signing
• Deal type
• Specific therapy focus
• For easy access, every deal record links to an online version, and where available, the full contract document.
• Critical Questions Answered

By analyzing actual contract agreements where available, this report provides definitive answers to critical questions such as:

• What specific rights are granted in each agreement?
• What exclusivity terms apply?
• How is the deal structured financially? (Upfronts, milestones, royalties)
• How are sales and payments audited?
• Who controls development, manufacturing, and commercialization?
• How is intellectual property handled?
• How are confidentiality and publication rights managed?
• Under what conditions can a deal be terminated?
• What dispute resolution mechanisms are in place?
• What happens in the event of a change in ownership?
• Gain the competitive edge-explore the report today.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner at discovery stage?

• 2.1. Introduction
• 2.2. The role of discovery stage partnering
  • 2.2.1. In-licensing at discovery stage
  • 2.2.2. Out-licensing at discovery stage
• 2.3. Difference between discovery, preclinical and clinical stage deals
• 2.4. Reasons for entering into discovery stage partnering deals
  • 2.4.1. Licensors reasons for entering discovery stage deals
  • 2.4.2. Licensees reasons for entering discovery stage deals
• 2.5. The future of discovery stage partnering deals

Chapter 3 - Discovery stage deal strategies and structure

• 3.1. Introduction
• 3.2. At what stage do companies partner?
  • 3.2.1. Partnering early in pharmaceutical/biotech
  • 3.2.1.1. Discovery and preclinical stage partnering case studies
  • 3.2.1.1.a. Case study 1
  • 3.2.1.1.b. Case study 2
  • 3.2.1.1.c. Case study 3
  • 3.2.1.1.d. Case study 4
  • 3.2.2. Partnering later in pharmaceutical/biotech
  • 3.2.2.1. Clinical stage partnering case studies
  • 3.2.2.1.a. Case study 5
  • 3.2.2.1.b. Case study 6
  • 3.2.2.1.c. Case study 7
  • 3.2.2.1.d. Case study 8
• 3.3. Early and later stage partnering - a risk/cost comparison
• 3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
• 3.5. Pure versus multi-component partnering deals
• 3.6. Pure licensing agreement structure
  • 3.6.1. Example pure licensing agreements
  • 3.6.1.a. Case study 9
  • 3.6.1.b. Case study 10
• 3.7. Multicomponent discovery stage partnering agreements
  • 3.7.1.a. Example multicomponent early stage clauses
  • 3.7.1.a. Case study 11
  • 3.7.1.b. Case study 12

Chapter 4 - Discovery stage partnering payment strategies

• 4.1. Introduction
• 4.2. Discovery stage payment strategies
• 4.3. Payment options
  • 4.3.1. Headline values
  • 4.3.2. Upfront payments
  • 4.3.2.1. Conditionality of upfront payments
  • 4.3.3. Loans
  • 4.3.4. Convertible loans
  • 4.3.5. Equity
  • 4.3.6. R&D funding
  • 4.3.7. Licensing fees
  • 4.3.8. Milestone payments
  • 4.3.9. Royalty payments
  • 4.3.9.1. Issues affecting royalty rates
  • 4.3.9.2. Royalties on combination products
  • 4.3.9.2.a. Case study 13
  • 4.3.9.3. Guaranteed minimum/maximum annual payments
  • 4.3.9.4. Royalty stacking
  • 4.3.9.5. Royalties and supply/purchase contracts
  • 4.3.10. Quids
  • 4.3.11. Option payments

Chapter 5 - Trends in discovery stage deal making

• 5.1. Introduction
• 5.2. Discovery stage partnering over the years
  • 5.2.1. Attributes of discovery deals
• 5.3. Discovery stage partnering by deal type
• 5.4. Discovery stage partnering by disease type
• 5.5. Partnering by discovery stage technology type
• 5.6. Discovery stage partnering by most active company, 2020 to 2026

Chapter 6 - Payment terms for discovery stage partnering

• 6.1. Introduction
• 6.2. Guidelines for discovery stage payment terms
  • 6.2.1. Upfront payments
  • 6.2.2. Milestone payments
  • 6.2.3. Royalty payments
• 6.3. Discovery stage payment terms - deal data analysis
  • 6.3.1. Public data
  • 6.3.2. Survey data
• 6.4. Payment terms analysis
  • 6.4.1. Discovery stage headline values
  • 6.4.2. Discovery stage deal upfront payments
  • 6.4.3. Discovery stage deal milestone payments
  • 6.4.4. Discovery stage royalty rates

Chapter 7 - Leading discovery stage deals

• 7.1. Introduction
• 7.2. Top discovery stage deals by value

Chapter 8 - Top 25 most active discovery stage dealmakers

• 8.1. Introduction
• 8.2. Top 25 most active discovery stage dealmakers

Chapter 9 - Discovery stage partnering contracts directory

• 9.1. Introduction
• 9.2. Discovery stage deals with contracts 2020 to 2026

Chapter 10 - Discovery stage deal making by development stage

• 10.1. Introduction
• 10.2. Deals by discovery stage

Appendices

• Appendix 1 - Discovery stage dealmaking by companies A-Z
• Appendix 2 - Discovery stage dealmaking by industry sector
• Appendix 3 - Discovery stage dealmaking by stage of development
• Appendix 4 - Discovery stage dealmaking by therapy area
• Appendix 5 - Discovery stage dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
• Figure 3: Components of the pure licensing deal structure
• Figure 4: Payment options for discovery stage partnering deals
• Figure 5: Issues affecting royalty rates
• Figure 6: Discovery stage partnering frequency
• Figure 7: Discovery stage partnering by deal type
• Figure 8: Discovery stage partnering by disease type
• Figure 9: Discovery stage partnering by technology type
• Figure 10: Top 25 most active discovery stage dealmakers
• Figure 11: Review of median upfront payments for discovery stage deals
• Figure 12: Review of median milestone payments for discovery stage deals
• Figure 13: Review of median royalty payments for discovery stage deals
• Figure 14: Discovery stage deals with a headline value
• Figure 15: Discovery stage deals with an upfront value
• Figure 16: Discovery stage deals with a milestone value
• Figure 17: Discovery stage deals with a royalty rate value
• Figure 18: Top discovery stage deals by deal value
• Figure 19: Most active discovery stage dealmakers